LNP Manufacturing Cartridges Market in the United States | Report – IndexBox

United States LNP Manufacturing Cartridges Market 2026 Analysis and Forecast to 2035

Executive Summary

Key Findings

• The United States LNP manufacturing cartridges market is projected to grow at a compound annual rate in the mid-to-high teens through 2035, driven by the expanding pipeline of nucleic acid therapeutics and the shift from batch to continuous flow LNP production.
• GMP-grade cartridges account for an estimated 55–65% of unit demand in 2026, reflecting regulatory emphasis on process consistency and the scaling of clinical and commercial LNP manufacturing within the United States.
• Domestic production capacity is constrained by high-precision micromachining and GMP cleanroom assembly bottlenecks; the market relies on imports for 35–45% of total cartridge supply, primarily from Germany, Japan, and South Korea.

Market Trends

Observed Bottlenecks

Specialized polymer substrate sourcing and qualification
High-precision micromachining capacity
GMP-grade cleanroom assembly capacity
Supply chain for platform-specific design IP

• Transition from proprietary platform-locked cartridges toward open-architecture designs is accelerating, as CDMOs and biopharmas seek supplier flexibility and multi-platform compatibility for tech transfer.
• Demand for high-throughput screening cartridges is rising at an above-average rate (estimated 18–22% CAGR) as early-stage discovery workflows adopt parallel LNP formulation screening for mRNA, siRNA, and gene editing payloads.
• Single-use GMP cartridges are increasingly designed with integrated process analytical technology (PAT) sensors, enabling real-time LNP size and polydispersity monitoring without breaking sterility.

Key Challenges

• Supply bottlenecks for specialized cyclic olefin copolymer (COC) and cyclo-olefin polymer (COP) substrates—the preferred materials for bio-inert, low-autofluorescence cartridges—create lead time volatility, with order-to-delivery cycles extending to 12–18 months for qualified grades.
• Regulatory qualification of new cartridge designs under FDA cGMP (21 CFR Part 211) and EMA GMP Annex 1 requires extended validation timelines, often 6–12 months per cartridge type, slowing supplier onboarding and increasing switching costs.
• Price pressure from internal production ambitions of large CDMOs, which are investing in captive microfluidic chip fabrication, threatens to commoditize standard research-grade cartridges and compress margins for pure-play consumable vendors.

Market Overview

The United States LNP manufacturing cartridges market represents the physical consumable interface for producing lipid nanoparticles encapsulating nucleic acid therapeutics. These cartridges—typically microfluidic mixing devices based on staggered herringbone or T-junction geometries—are classified under HS codes 392690 (articles of plastics) and 901890 (medical instruments). The product is a tangible, single-use assembly supplied in GMP-compliant packaging, designed for one-time use in process development (PD), clinical trial material (CTM) manufacturing, and commercial-scale GMP production.

The market is characterized by high technical specificity: each cartridge must deliver reproducible nanoparticle size, encapsulation efficiency, and low polydispersity index under controlled flow conditions. Buyers—process development scientists, manufacturing heads, and procurement specialists at biopharmaceutical firms and CDMOs—evaluate cartridges based on lot-to-lot consistency, platform compatibility, sterility assurance, and total cost of use including instrument lock-in costs.

United States demand is structurally linked to the global nucleic acid therapeutic pipeline, with roughly 40% of all LNP-encapsulated investigational drugs in phase II or later originating from US-headquartered sponsors. The country also hosts the largest installed base of microfluidic LNP formulation systems, estimated at 800–1,200 units across biopharma, CDMO, and academic sites. This infrastructure generates recurring consumable demand, as each GMP batch typically consumes several cartridges (one per formulation condition plus spares), and process development runs often use 20–100 cartridges per project. The market is therefore not driven by discrete capital equipment replacement cycles but by the volume of LNP batches produced, which itself tracks clinical trial starts, regulatory submissions, and commercial manufacturing scale-up.

Market Size and Growth

While precise total market revenue is not publicly disclosed, a defensible estimate places the United States LNP manufacturing cartridges market in the range of USD 180–260 million in 2026, with unit volume between 80,000 and 120,000 cartridges. Growth is being propelled by two primary vectors: the expansion of approved LNP-based products (e.g., mRNA vaccines, siRNA therapies) and the increase in R&D activity for next-generation modalities such as CRISPR-Cas9 delivery and self-amplifying RNA. The forecast CAGR from 2026 to 2035 is projected at 14–18%, implying that unit demand could more than triple over the horizon. Volume growth outpaces value growth slightly due to price erosion in research-grade segments, partially offset by premium pricing for GMP and integrated-sensor cartridges.

Macro drivers include the broader nucleic acid therapeutics market, expected to grow at a CAGR of 12–16% globally, and the specific push toward decentralized manufacturing—a trend accelerated by the pandemic that increases the number of formulation sites using LNP cartridges. Additionally, regulatory guidance from the FDA and ICH (Q7, Q9, Q10) emphasizing process validation and quality-by-design is pushing developers to invest in higher volumes of process characterization batches, each requiring multiple cartridges. The replacement of legacy batch-mixing methods (e.g., ethanol injection) with continuous-flow LNP production is also expected to increase cartridge consumption per unit of finished drug product, as continuous processes run longer but require periodic cartridge changes to maintain sterility.

Demand by Segment and End Use

Segment demand is best understood by cartridge grade. GMP/clinical-grade cartridges represent the largest share, likely 55–65% of units and 70–80% of value in 2026, driven by clinical and commercial manufacturing needs. Research/pre-clinical-grade cartridges account for 20–30% of units, used primarily in early formulation screening and optimization. High-throughput screening cartridges—often designed for multi-channel parallel mixing—capture a smaller volume (10–15%) but exhibit the fastest growth rate (18–22% CAGR) as sponsors screen dozens of formulation conditions per candidate.

By application, mRNA vaccine and therapeutic LNP cartridges dominate demand (at least 50% of units), reflecting the legacy of COVID-19 vaccine production and a pipeline rich in oncology and infectious disease mRNA assets. siRNA LNPs form the second-largest application (25–30%), driven by approved therapies such as patisiran and vutrisiran and a growing pipeline for rare liver diseases. Gene editing LNPs, including CRISPR-Cas9 ribonucleoprotein delivery, account for roughly 10–15% of units but are expanding rapidly as preclinical programs advance.

Other nucleic acid LNPs (e.g., DNA vaccines, antisense oligonucleotides) constitute the remainder.

End-use sectors are concentrated in biopharmaceutical companies and CDMOs, which together account for an estimated 80–85% of cartridge procurement. Academic and government research institutes contribute 10–15%, while startup therapeutics developers—often operating with limited capital—represent a smaller but innovation-sensitive share. By value chain structure, platform-locked or proprietary cartridges (designed exclusively for a specific instrument vendor) still command roughly 60% of the market, but open-architecture compatible cartridges are gaining share as CDMOs and multi-platform users push for standardization. This shift is expected to accelerate after 2028 as interoperability standards mature.

Prices and Cost Drivers

Pricing for LNP manufacturing cartridges exhibits wide variation based on grade, volume, and platform specificity. Research-grade cartridges (typically polymer-based, non-GMP) are priced in the range of USD 50–150 per unit for low volumes (single-digit quantities), falling to USD 30–80 per unit for bulk orders of 500 or more. GMP-grade cartridges—supplied with sterility assurance, lot-specific documentation, and validation packages—range from USD 200 to 800 per unit at low volumes, with tiered discounts for high-volume contracts (USD 150–500 per unit for annual commitments exceeding 1,000 pieces). High-throughput screening cartridges, which require more complex microchannel architectures and often include optical windows for real-time measurement, command USD 300–1,000 per unit.

Cost drivers are predominantly upstream. The base polymer—typically cyclic olefin copolymer (COC) or cyclo-olefin copolymer (COP)—represents 15–25% of manufacturing cost, but supply constraints for medical-grade material can elevate raw material costs by 30–40% during shortages. Micromachining and hot-embossing precision tooling accounts for another 20–30%, while GMP-grade cleanroom assembly, packaging, and sterilization (ethylene oxide or gamma) add 20–25%.

Service and support contracts, including process development packages and validation runs, are bundled into initial pricing for large customers, effectively raising the average revenue per cartridge for first-time adopters. Platform instrument lock-in also functions as a pricing lever: vendors that sell both the cartridge and the formulation instrument can bundle lease or service fees, making the cartridge unit price appear lower while recovering margin through recurring instrument payments.

Suppliers, Manufacturers and Competition

The United States LNP manufacturing cartridges market is served by a mix of global specialist manufacturers, integrated platform innovators, and CDMO-affiliated producers. The competitive landscape can be characterized by four archetypes: integrated platform innovators (e.g., companies selling both formulation instruments and proprietary cartridges), specialized consumable manufacturers (focusing exclusively on cartridge fabrication without instrument lock-in), CDMOs with proprietary process platforms (which produce cartridges for internal use and may also supply external partners), and materials science specialists that develop novel polymer substrates for improved bio-inertness or optical clarity. The market exhibits moderate concentration: the top five suppliers likely control 55–65% of unit volume, but a growing tail of smaller niche vendors—particularly in open-architecture supplies and high-throughput screening—is fragmenting the research-grade segment.

Competition is shaped by technical qualification, regulatory validation support, and supply reliability. Buyers typically maintain dual or triple sourcing for GMP-grade cartridges to mitigate supply risk, but switching suppliers requires a requalification timeline of 4–9 months, creating switching costs. US-based suppliers benefit from proximity to customers and the ability to offer rapid technical support, while European and Asian suppliers compete on lower unit prices (estimated 10–25% below US domestic pricing for comparable grades) and specialized polymer expertise.

The CDMO segment is an emerging competitive force: several large CDMOs are investing in captive microfluidic chip fabrication to reduce external consumable dependence, though this is unlikely to fully displace the merchant cartridge market due to scale and specialization advantages.

Domestic Production and Supply

United States domestic production of LNP manufacturing cartridges is concentrated in specialized manufacturing sites located in the Northeast, the San Francisco Bay Area, and the Research Triangle region of North Carolina—all areas with high density of biopharmaceutical R&D and CDMO operations. These facilities typically comprise Class 7 (ISO 5) or better cleanrooms for cartridge assembly, with parallel lines for precision micromachining, solvent bonding, and packaging.

Domestic capacity is estimated at 50,000–80,000 units per year as of 2026, constrained primarily by the availability of GMP-grade cleanroom square footage and the throughput of high-precision micro-milling and embossing equipment. Several US producers have announced capacity expansions since 2023, targeting an additional 30–50% capacity within three years, but these plans face execution risks related to equipment lead times (20–30 months for specialized micro-machining tools) and qualified workforce availability.

The supply chain for domestic production relies on imported specialty polymer substrates. High-purity cyclic olefin copolymer (COC) resin is sourced predominantly from Japanese and German chemical suppliers, with lead times extending to 6–10 months for qualified medical-grade lots. Domestic producers also depend on imported micro-molding tooling from Switzerland, Japan, and Germany, further embedding the US supply chain in global sourcing networks. As a result, while final assembly occurs domestically, the overall supply model is import-dependent for critical inputs, creating vulnerability to trade disruptions and freight cost variability.

Domestic production is advantageous for just-in-time delivery and rapid technical iteration during process development, but pure domestic end-to-end self-sufficiency is unlikely to be achieved within the forecast horizon.

Imports, Exports and Trade

The United States is a net importer of LNP manufacturing cartridges, with imports estimated to supply 35–45% of domestic consumption by volume in 2026. Primary source countries are Germany (leading in high-precision microfluidic chip fabrication), Japan (dominant in specialty polymer molding), and South Korea (growing CDMO-affiliated cartridge production). Imports enter under HS code 392690 (articles of plastics, n.e.s.) or 901890 (instruments for medical uses), with the latter classification typically carrying lower duties for validated medical devices.

Tariff treatment varies: cartridges classified as medical devices (901890) may enter duty-free under WTO medical device agreements, while those under 392690 face a general duty rate of 5–6% ad valorem, subject to trade agreement preferences. The US-China trade dynamic is relevant: limited Chinese production of LNP cartridges exists, but geopolitical and regulatory hurdles (FDA GMP audits, IP protection) restrict significant sourcing from China for GMP-grade products, though research-grade cartridges from Chinese suppliers are gaining some traction.

Exports from the United States are modest, likely in the range of 5–10% of domestic production volume, directed primarily to European and Canadian biopharma clients who prefer US-made cartridges for validation and regulatory familiarity. The trade balance is structurally negative, but the trade data is complicated by the frequent bundling of cartridges with instrument sales and service contracts, which may not be captured in discrete customs lines. Over the forecast period, import dependence is expected to increase slightly as domestic demand growth outpaces capacity additions, unless major new production facilities are announced.

Strategic procurement specialists in the US are actively working to qualify alternative non-US suppliers to diversify risk, with a notable trend toward dual-sourcing from South Korean and Singaporean CDMO-backed facilities.

Distribution Channels and Buyers

Distribution of LNP manufacturing cartridges in the United States follows a direct-sales model for large-volume buyers and a distributor/representative model for smaller accounts. The dominant channel is direct procurement agreements between cartridge manufacturers and biopharmaceutical companies or CDMOs, often negotiated on an annual or multi-year basis with committed volume and price escalators. These contracts are typically managed by dedicated account managers from the supplier side, supported by field application scientists who assist with process development integration.

For start-ups and academic labs, cartridges are more commonly purchased through online catalogs or specialized life science distributors such as MilliporeSigma, Thermo Fisher Scientific, or regional scientific supply houses, though the latter are less common for GMP-grade products given the need for regulatory documentation and cold-chain logistics.

Buyer groups include process development scientists at innovator firms who influence cartridge selection based on performance in early formulation studies; manufacturing/operations heads who authorize GMP purchases; procurement and supply chain specialists who negotiate tiered pricing and manage supplier qualification; and CDMO business development teams who select cartridges when offering LNP manufacturing services to clients. The purchase decision for GMP-grade cartridges involves a cross-functional team and a formal supplier qualification process (audit, paper review, technical evaluation) that can span 3–6 months.

For research-grade cartridges, decision cycles are shorter (2–4 weeks) and driven by the individual scientist. A notable trend is the rise of cartridge subscription or consignment inventory models, where suppliers maintain stock at the buyer’s facility and invoices are triggered upon use, reducing carrying costs for high-throughput CDMOs.

Regulations and Standards

Typical Buyer Anchor

Process Development Scientists
Manufacturing/Operations Heads
Procurement & Supply Chain Specialists

Regulatory compliance is the single most demanding factor in the United States LNP manufacturing cartridges market. Cartridges used in clinical or commercial manufacturing must meet FDA cGMP requirements under 21 CFR Part 211 (drug product) and, depending on classification, may also be subject to the Quality System Regulation (21 CFR Part 820) if the cartridge qualifies as a medical device component. International alignment is driven by ICH Q7 (GMP for active pharmaceutical ingredients), Q9 (risk management), and Q10 (pharmaceutical quality system).

For sterilized single-use cartridges, validation must demonstrate bioburden control, endotoxin limits, and sterility assurance level (SAL) of 10^-6. EMA GMP Annex 1 (manufacture of sterile medicinal products) is also relevant for cartridges exported to European markets, and US buyers increasingly require dual FDA/EMA compliance for global tech transfer.

Cartridge manufacturers typically operate under ISO 13485 (quality management for medical devices) even if the cartridge is not strictly classified as a device, because buyers demand this certification to simplify regulatory filing. The FDA has been active in issuing guidance on continuous manufacturing of drug products, including LNP formulation, which indirectly drives demand for well-characterized, validated cartridges. Cartridge suppliers must also comply with USP and (particulate matter) if the cartridge is used in compounding or as part of a final drug product contact surface.

Regulatory expectations around extractables and leachables are increasingly stringent, with USP and relevant for polymer-based assemblies. The absence of harmonized international standards for microfluidic cartridges creates a patchwork validation burden, favoring suppliers with deep regulatory expertise and proven dossiers.

Market Forecast to 2035

Over the 2026–2035 period, the United States LNP manufacturing cartridges market is expected to expand at a CAGR of 14–18%, translating to a roughly three- to fourfold increase in unit volume by the end of the horizon. The most dynamic growth sub-segments will be GMP-grade cartridges for commercial-scale production (as more LNP therapeutics achieve approval) and high-throughput screening cartridges (as the pre-clinical pipeline diversifies beyond mRNA into siRNA, gene editing, and emerging modalities). The forecast reflects several assumptions: that the number of US-based clinical trials using LNP formulation grows at a 9–12% annual rate; that commercial LNP manufacturing capacity (excluding vaccines) at least doubles by 2030; and that the shift to continuous flow manufacturing is largely completed in the CDMO segment by 2032.

Pricing evolution is expected to be moderate. Research-grade cartridge prices may decline 10–15% over the decade due to commoditization and increased competition from lower-cost manufacturers, while GMP-grade prices are likely to remain stable or edge upward as regulatory expectations around PAT integration and documentation increase. The premium for high-throughput cartridges should persist given the technical complexity and small production volumes. The overall value growth will thus be slightly slower than volume growth, with revenue potentially increasing 2.5–3 times from 2026 base levels.

Domestic production share may stabilize around 55–65% if planned capacity expansions materialize, but import dependence for polymer substrates is likely to persist. Wild-card factors include rapid expansion of decentralized manufacturing nodes (which could boost cartridge demand but also invite local production) and potential shifts in regulatory filing requirements (e.g., FDA mandating use of single-use sensors, which would increase cartridge value per unit).

Market Opportunities

The clearest near-term opportunity lies in open-architecture compatible cartridges, which address the pain point of platform lock-in and are favored by CDMOs and multi-platform biopharmas. Suppliers that can offer a validated, off-the-shelf cartridge that works across multiple instrument types (e.g., Precision NanoSystems, Dolomite, Micronit, and others) will capture a growing share of the market, especially as CDMOs seek to standardize consumable sourcing across client projects.

A second opportunity is in next-generation cartridge designs that integrate real-time PAT (e.g., dynamic light scattering, UV-Vis, or NIR sensors) directly into the flow path. Such cartridges enable quality-by-design compliance by providing process data at the point of formulation, reducing the need for offline testing and facilitating continuous manufacturing. The market premium for integrated-sensor cartridges could be 40–60% over standard GMP cartridges, representing a high-value niche.

Archetype
Core Components
Assay Formulation
Regulated Supply
Application Support
Commercial Reach

Integrated Platform Innovator
High
High
High
High
High

Specialized Consumables Manufacturer
High
High
Medium
High
Medium

CDMO with Proprietary Process
Selective
Medium
High
Medium
Medium

Materials Science Specialist
Selective
Medium
Medium
Medium
Medium

This report is an independent strategic market study that provides a structured, commercially grounded analysis of the market for LNP manufacturing cartridges in the United States. It is designed for manufacturers, investors, suppliers, distributors, contract development and manufacturing organizations, and strategic entrants that need a clear view of market boundaries, demand architecture, supply capability, pricing logic, and competitive positioning.

The analytical framework is designed to work both for a single advanced product and for a broader generic product category, where the market has to be understood through workflows, applications, buyer environments, and supply capabilities rather than through one narrow statistical code. The study does not treat public market estimates or raw customs statistics as a standalone source of truth; instead, it reconstructs the market through modeled demand, evidenced supply, technology mapping, regulatory context, pricing logic, and country capability analysis.

The report defines the market scope around LNP manufacturing cartridges as Single-use, microfluidic-based consumable cartridges designed for the scalable, reproducible, and GMP-compliant formulation of lipid nanoparticles (LNPs) for nucleic acid delivery. It examines the market as an integrated system shaped by product architecture, technological requirements, end-use demand, manufacturing feasibility, outsourcing patterns, supply-chain bottlenecks, pricing behavior, and strategic positioning. Historical analysis typically covers 2012 to 2025, with forward-looking scenarios through 2035.

What this report is about

At its core, this report explains how the market for LNP manufacturing cartridges actually functions. It identifies where demand originates, how supply is organized, which technological and regulatory barriers influence adoption, and how value is distributed across the value chain. Rather than describing the market only in broad terms, the study breaks it into analytically meaningful layers: product scope, segmentation, end uses, customer types, production economics, outsourcing structure, country roles, and company archetypes.

The report is particularly useful in markets where buyers are highly specialized, suppliers differ significantly in technical depth and regulatory readiness, and the commercial landscape cannot be understood only through top-line market size figures. In this context, the study is designed not only to estimate the size of the market, but to explain why the market has that size, what drives its growth, which subsegments are the most attractive, and what it takes to compete successfully within it.

Research methodology and analytical framework

The report is based on an independent analytical methodology that combines deep secondary research, structured evidence review, market reconstruction, and multi-level triangulation. The methodology is designed to support products for which there is no single clean official dataset capturing the full market in a directly usable form.

The study typically uses the following evidence hierarchy:

• official company disclosures, manufacturing footprints, capacity announcements, and platform descriptions;
• regulatory guidance, standards, product classifications, and public framework documents;
• peer-reviewed scientific literature, technical reviews, and application-specific research publications;
• patents, conference materials, product pages, technical notes, and commercial documentation;
• public pricing references, OEM/service visibility, and channel evidence;
• official trade and statistical datasets where they are sufficiently scope-compatible;
• third-party market publications only as benchmark triangulation, not as the primary basis for the market model.

The analytical framework is built around several linked layers.

First, a scope model defines what is included in the market and what is excluded, ensuring that adjacent products, downstream finished goods, unrelated instruments, or broader chemical categories do not distort the market boundary.

Second, a demand model reconstructs the market from the perspective of consuming sectors, workflow stages, and applications. Depending on the product, this may include Oncology mRNA vaccines, Infectious disease mRNA vaccines, Rare disease siRNA therapies, Gene editing therapies, and Personalized cancer neoantigen vaccines across Biopharmaceuticals, Contract Development & Manufacturing Organizations (CDMOs), Academic & Government Research Institutes, and Start-up Therapeutics Developers and Process Development & Optimization, Clinical Trial Material Manufacturing, and Commercial-Scale GMP Manufacturing. Demand is then allocated across end users, development stages, and geographic markets.

Third, a supply model evaluates how the market is served. This includes Medical-grade polymers (e.g., COP, COC), High-purity silicones & adhesives, Specialty glass substrates, and Validated raw materials for GMP, manufacturing technologies such as Microfluidic Mixing (e.g., staggered herringbone, T-junction), Polymer/Glass-based Chip Fabrication, Surface Chemistry for Bio-inertness, and Single-Use Assembly & Sterilization, quality control requirements, outsourcing and CDMO participation, distribution structure, and supply-chain concentration risks.

Fourth, a country capability model maps where the market is consumed, where production is materially feasible, where manufacturing capability is limited or emerging, and which countries function primarily as innovation hubs, supply nodes, demand centers, or import-reliant markets.

Fifth, a pricing and economics layer evaluates price corridors, cost drivers, complexity premiums, outsourcing logic, margin structure, and switching barriers. This is especially relevant in markets where product grade, purity, customization, regulatory burden, or service model materially influence economics.

Finally, a competitive intelligence layer profiles the leading company types active in the market and explains how strategic roles differ across upstream suppliers, research-grade providers, OEM partners, CDMOs, integrated platform companies, and distributors.

Product-Specific Analytical Anchors

• Key applications: Oncology mRNA vaccines, Infectious disease mRNA vaccines, Rare disease siRNA therapies, Gene editing therapies, and Personalized cancer neoantigen vaccines
• Key end-use sectors: Biopharmaceuticals, Contract Development & Manufacturing Organizations (CDMOs), Academic & Government Research Institutes, and Start-up Therapeutics Developers
• Key workflow stages: Process Development & Optimization, Clinical Trial Material Manufacturing, and Commercial-Scale GMP Manufacturing
• Key buyer types: Process Development Scientists, Manufacturing/Operations Heads, Procurement & Supply Chain Specialists, and CDMO Business Development
• Main demand drivers: Pipeline growth of nucleic acid therapeutics, Shift from batch to continuous/flow manufacturing for LNPs, Demand for scalability and tech transfer robustness, Regulatory emphasis on process consistency and quality, and Expansion of decentralized/regional manufacturing
• Key technologies: Microfluidic Mixing (e.g., staggered herringbone, T-junction), Polymer/Glass-based Chip Fabrication, Surface Chemistry for Bio-inertness, and Single-Use Assembly & Sterilization
• Key inputs: Medical-grade polymers (e.g., COP, COC), High-purity silicones & adhesives, Specialty glass substrates, and Validated raw materials for GMP
• Main supply bottlenecks: Specialized polymer substrate sourcing and qualification, High-precision micromachining capacity, GMP-grade cleanroom assembly capacity, and Supply chain for platform-specific design IP
• Key pricing layers: Cartridge Unit Price (volume-tiered), Platform Instrument Lock-in/Lease, Service & Support Contracts, and Process Development/Validation Packages
• Regulatory frameworks: FDA cGMP (21 CFR Part 211), EMA GMP Annex 1, ISO 13485 (if classified as medical device component), and ICH Q7, Q9, Q10 Guidelines

Product scope

This report covers the market for LNP manufacturing cartridges in its commercially relevant and technologically meaningful form. The scope typically includes the product itself, its major product configurations or variants, the critical technologies used to produce or deliver it, the core input categories required for manufacturing, and the services directly associated with its commercial supply, quality control, or integration into end-user workflows.

Included within scope are the product forms, use cases, inputs, and services that are necessary to understand the actual addressable market around LNP manufacturing cartridges. This usually includes:

• core product types and variants;
• product-specific technology platforms;
• product grades, formats, or complexity levels;
• critical raw materials and key inputs;
• manufacturing, synthesis, purification, release, or analytical services directly tied to the product;
• research, commercial, industrial, clinical, diagnostic, or platform applications where relevant.

Excluded from scope are categories that may be technologically adjacent but do not belong to the core economic market being measured. These usually include:

• downstream finished products where LNP manufacturing cartridges is only one embedded component;
• unrelated equipment or capital instruments unless explicitly part of the addressable market;
• generic reagents, chemicals, or consumables not specific to this product space;
• adjacent modalities or competing product classes unless they are included for comparison only;
• broader customs or tariff categories that do not isolate the target market sufficiently well;
• Bulk lipids and raw chemical inputs, Final filled drug product vials/syringes, Standalone LNP manufacturing equipment without cartridge dependency, Research-grade, non-GMP pipettes or manual mixing tools, Chromatography columns or filtration membranes used downstream, Polymer-based nanoparticle formulation systems, Liposome extrusion equipment and consumables, Viral vector production consumables, Cell culture bioreactors and media, and Downstream purification resins and filters.

The exact inclusion and exclusion logic is always a critical part of the study, because the quality of the market estimate depends directly on disciplined scope boundaries.

Product-Specific Inclusions

• GMP-grade single-use cartridges for LNP formulation
• Cartridges designed for integrated benchtop and commercial-scale LNP manufacturing platforms
• Cartridges enabling microfluidic-based nanoprecipitation
• Cartridges for mRNA-LNP, siRNA-LNP, and gene editing therapeutic formulation

Product-Specific Exclusions and Boundaries

• Bulk lipids and raw chemical inputs
• Final filled drug product vials/syringes
• Standalone LNP manufacturing equipment without cartridge dependency
• Research-grade, non-GMP pipettes or manual mixing tools
• Chromatography columns or filtration membranes used downstream

Adjacent Products Explicitly Excluded

• Polymer-based nanoparticle formulation systems
• Liposome extrusion equipment and consumables
• Viral vector production consumables
• Cell culture bioreactors and media
• Downstream purification resins and filters

Geographic coverage

The report provides focused coverage of the United States market and positions United States within the wider global industry structure.

The geographic analysis explains local demand conditions, domestic capability, import dependence, buyer structure, qualification requirements, and the country’s strategic role in the broader market.

Depending on the product, the country analysis examines:

• local demand structure and buyer mix;
• domestic production and outsourcing relevance;
• import dependence and distribution channels;
• regulatory, validation, and qualification constraints;
• strategic outlook within the wider global industry.

Geographic and Country-Role Logic

• US/EU: Dominant R&D, clinical manufacturing, and primary end-markets
• Asia-Pacific (e.g., China, South Korea, Japan): Growing therapeutic pipeline and manufacturing capacity
• Emerging Hubs (e.g., Singapore): CDMO and regional supply node development

What questions this report answers

This report is designed to answer the questions that matter most to decision-makers evaluating a complex product market.

1. Market size and direction: how large the market is today, how it has developed historically, and how it is expected to evolve over the next decade.
2. Scope boundaries: what exactly belongs in the market and where the boundary should be drawn relative to adjacent product classes, technologies, and downstream applications.
3. Commercial segmentation: which segmentation lenses are commercially meaningful, including type, application, customer, workflow stage, technology platform, grade, regulatory use case, or geography.
4. Demand architecture: which industries consume the product, which applications create the strongest value pools, what drives adoption, and what barriers slow or limit penetration.
5. Supply logic: how the product is manufactured, which critical inputs matter, where bottlenecks exist, how outsourcing works, and which quality or regulatory burdens shape supply.
6. Pricing and economics: how prices differ across segments, which factors drive cost and yield, and where complexity, qualification, or customer lock-in create defensible economics.
7. Competitive structure: which company archetypes matter most, how they differ in capabilities and positioning, and where strategic whitespace may still exist.
8. Entry and expansion priorities: where to enter first, which segments are most attractive, whether to build, buy, or partner, and which countries are the most suitable for manufacturing or commercial expansion.
9. Strategic risk: which operational, commercial, qualification, and market risks must be managed to support credible entry or scaling.

Who this report is for

This study is designed for a broad range of strategic and commercial users, including:

• manufacturers evaluating entry into a new advanced product category;
• suppliers assessing how demand is evolving across customer groups and use cases;
• CDMOs, OEM partners, and service providers evaluating market attractiveness and positioning;
• investors seeking a more robust market view than off-the-shelf benchmark estimates alone can provide;
• strategy teams assessing where value pools are moving and which capabilities matter most;
• business development teams looking for attractive product niches, customer groups, or expansion markets;
• procurement and supply-chain teams evaluating country risk, supplier concentration, and sourcing diversification.

Why this approach is especially important for advanced products

In many high-technology, biopharma, and research-driven markets, official trade and production statistics are not sufficient on their own to describe the true market. Product boundaries may cut across multiple tariff codes, several product categories may be bundled into the same official classification, and a meaningful share of activity may take place through customized services, captive supply, platform relationships, or technically specialized channels that are not directly visible in standard statistical datasets.

For this reason, the report is designed as a modeled strategic market study. It uses official and public evidence wherever it is reliable and scope-compatible, but it does not force the market into a purely statistical framework when doing so would reduce analytical quality. Instead, it reconstructs the market through the logic of demand, supply, technology, country roles, and company behavior.

This makes the report particularly well suited to products that are innovation-intensive, technically differentiated, capacity-constrained, platform-dependent, or commercially structured around specialized buyer-supplier relationships rather than standardized commodity trade.

Typical outputs and analytical coverage

The report typically includes:

• historical and forecast market size;
• market value and normalized activity or volume views where appropriate;
• demand by application, end use, customer type, and geography;
• product and technology segmentation;
• supply and value-chain analysis;
• pricing architecture and unit economics;
• manufacturer entry strategy implications;
• country opportunity mapping;
• competitive landscape and company profiles;
• methodological notes, source references, and modeling logic.

The result is a structured, publication-grade market intelligence document that combines quantitative modeling with commercial, technical, and strategic interpretation.

Source link

Novartis Begins Construction on Denton, Texas Radioligand Therapy Facility

Novartis Breaks Ground on Texas Radioligand Therapy Facility as Part of $23 Billion U.S. Expansion

Novartis has officially begun construction on a new radioligand therapy manufacturing facility in Denton, Texas, marking another major step in the pharmaceutical company’s multibillion-dollar expansion of its U.S. manufacturing and research operations.

Courtesy: photo by Furkan on pexels

The 46,000-square-foot facility will serve as Novartis’ first manufacturing site in Texas and its fifth radioligand therapy, or RLT, production site in the United States. The project is part of the company’s broader $23 billion investment strategy aimed at strengthening domestic pharmaceutical manufacturing and supply chain operations over the next five years.

Company officials said the Denton facility is expected to become operational in 2028 and will support the production of targeted cancer therapies for patients across the southern United States.

“Radioligand therapy is transforming how we treat cancer, and expanded manufacturing is essential to delivering these therapies at scale,” said Vas Narasimhan, CEO of Novartis. “Breaking ground in Denton further strengthens our US supply chain and helps ensure patients can receive these highly personalized treatments when and where they need them.”

Denton Facility Expands National Manufacturing Network

The groundbreaking ceremony included federal, state and local officials, including U.S. Under Secretary of Commerce for Industry and Security Jeffrey Kessler, Swiss Ambassador to the U.S. Ralf Heckner, Texas State Sen. Brent Hagenbuch, Texas State Rep. Andy Hopper and Denton Mayor Gerard Hudspeth.

The new facility will support Novartis’ expanding radioligand therapy network, which already includes sites in New Jersey, Indiana and California, along with another facility planned for Florida.

According to the company, radioligand therapy manufacturing requires highly specialized production and logistics coordination because treatments are customized for individual patients and delivered within narrow treatment windows. Novartis said its current network allows more than 99% of doses to be administered on the scheduled treatment day.

The company also expects the Denton project to generate new jobs in bioengineering, manufacturing, quality assurance and operations, contributing to regional economic development in North Texas.

“I’m pleased to welcome Novartis to Denton as their newest manufacturing location for their cancer therapies,” said Texas State Senator Brent Hagenbuch. “Their decision establishes a strong partnership and reflects the unique opportunity Denton provides to a well-educated workforce, and the unique access the new plant location will provide to the vibrant North Texas economy and rapidly growing state population.”

Construction Pipeline Includes Multiple U.S. Projects

The Texas project is one of several major construction and expansion initiatives currently underway as part of Novartis’ nationwide investment program.

In recent months, the company announced or began work on projects in North Carolina, California and Florida, including a biomedical research center in San Diego and a new manufacturing facility in Winter Park, Florida. The company also continues to expand existing RLT operations in Indianapolis and Millburn, New Jersey.

Novartis said the ongoing investments are intended to support domestic manufacturing of key medicines while improving supply chain resilience and treatment access.

Radioligand therapy has become a growing area of focus for pharmaceutical manufacturers because the technology targets cancer cells with radioactive compounds designed to minimize damage to surrounding healthy tissue. Novartis said it is currently studying the use of RLTs for several forms of cancer, including prostate, breast, lung, colon, pancreatic and brain cancers.

The company described its U.S. expansion as part of a long-term strategy to scale manufacturing capacity alongside the continued development of its oncology pipeline and emerging treatment technologies.

Originally reported by Novartis Pharma AG in Yahoo Finance.

Source link

U.S. manufacturing push and Q1 2026 results in focus

Amgen Inc. has announced a fresh $300 million U.S. manufacturing investment and reported first?quarter 2026 financial results, highlighting growth in product sales and margins.

Amgen Inc. has moved into the spotlight after announcing an additional $300 million investment in its U.S. manufacturing network and releasing its first?quarter 2026 financial results. The new capital commitment brings the company’s total U.S. manufacturing outlay over the past year to nearly $2 billion, underscoring its focus on domestic capacity and next?generation biologics production. At the same time, Amgen’s latest quarterly figures show continued revenue growth and solid profitability, reinforcing its position as a leading biotech player for U.S. investors.

According to a press release dated May 4, 2026, Amgen plans to allocate the $300 million to expand and modernize its U.S. manufacturing footprint, including advanced technologies and supply?chain resilience for key medicines. The company emphasized that the investment will support a reliable supply of therapies for patients and align with broader U.S. policy goals around onshoring critical drug production. PR Newswire as of May 4, 2026

On the financial side, Amgen reported first?quarter 2026 results on April 24, 2026, with product sales and overall revenue trending higher year?over?year. Earlier filings and third?party summaries indicate that the company’s quarterly revenue rose about 5.8% versus the same quarter of the prior year, while net margin and return on equity remained strong, reflecting disciplined cost management and pricing power in its core franchises. Stock Titan as of April 24, 2026

As of: 09.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Amgen Inc.
• Sector/industry: Biotechnology / Pharmaceuticals
• Headquarters/country: Thousand Oaks, California, United States
• Core markets: United States, Europe, Japan and other developed markets
• Key revenue drivers: Oncology, cardiovascular, inflammation and bone health franchises
• Home exchange/listing venue: Nasdaq (ticker: AMGN)
• Trading currency: U.S. dollar

Amgen Inc.: core business model

Amgen Inc. operates as a global biotechnology company focused on discovering, developing and commercializing innovative human therapeutics. The firm’s business model centers on proprietary biologic platforms and a diversified portfolio of marketed medicines, primarily in oncology, cardiovascular disease, inflammation and bone health. By investing heavily in research and development, Amgen aims to extend the lifecycle of existing products while advancing a pipeline of novel candidates that can address unmet medical needs.

Amgen’s strategy combines internal R&D with targeted acquisitions and collaborations, allowing it to broaden its therapeutic footprint without over?relying on any single indication. The company markets its products through a global commercial infrastructure, with a particularly strong presence in the United States, where it benefits from favorable reimbursement dynamics and a large patient base. This U.S.?centric exposure makes Amgen a relevant name for American retail investors seeking exposure to the biotech sector.

Main revenue and product drivers for Amgen Inc.

Amgen’s revenue is driven by a portfolio of established biologic brands, including therapies for cancer, cardiovascular risk reduction, inflammatory conditions and osteoporosis. These products typically command premium pricing and benefit from long?term treatment regimens, which support recurring sales and relatively predictable cash flows. Recent quarterly filings indicate that product sales have grown steadily, with total revenues rising to about $9.56 billion in the third quarter of 2025 from $8.50 billion a year earlier, reflecting both volume growth and favorable pricing dynamics. Stock Titan as of November 4, 2025

Within this portfolio, oncology and cardiovascular franchises have been key growth engines, supported by label expansions and new indications. Amgen’s ability to maintain high net margins and strong return on equity suggests effective cost control and pricing power, even as the company continues to invest in R&D and manufacturing. The additional $300 million U.S. manufacturing investment announced in May 2026 is expected to further strengthen supply reliability and operational efficiency, which can help protect margins and support long?term revenue growth.

Conclusion

Amgen Inc. is drawing attention from U.S. investors following a fresh $300 million U.S. manufacturing investment and solid first?quarter 2026 financial results. The company’s focus on expanding domestic production capacity aligns with broader policy trends and may enhance supply reliability for its key medicines. At the same time, continued revenue growth and strong profitability metrics suggest that Amgen’s core franchises remain resilient in a competitive biotech landscape.

For U.S. retail investors, Amgen offers exposure to a diversified biotech portfolio with significant domestic sales and a track record of disciplined capital allocation. However, the stock remains sensitive to regulatory developments, pricing pressures and pipeline execution, which can influence both near?term performance and long?term growth prospects. As with any equity, investors should weigh these factors carefully and consider their own risk tolerance before making decisions.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.

en | US0311621009 | AMGEN INC. | boerse | 69298087 | bgmi

Source link

Kelly leads 52 Republicans in rejecting Chinese auto, battery manufacturing in U.S.

U.S. Rep. Mike Kelly (R-PA) recently led 52 of his Republican colleagues in urging the Trump administration against making any trade decisions that would allow Chinese automotive and battery companies to manufacture their products in the United States.

“The U.S. auto industry is reaching a critical inflection point, as global dynamics and shifts in policy create opportunities for heavily subsidized Chinese automakers to gain momentum using non-market tactics,” wrote Rep. Kelly and the lawmakers in an April 30 letter sent to U.S. Treasury Secretary Scott Bessent, U.S. Commerce Secretary Howard Lutnick, and U.S. Trade Ambassador Jamieson Greer.

“If Chinese automotive companies were granted access to manufacture and sell vehicles and batteries in the U.S., we risk decimating U.S. manufacturing, eroding global market share for U.S. auto companies, and leaving consumers and businesses exposed to serious cybersecurity and surveillance threats,” they wrote. “This is not a winning strategy.”

In their letter, which was sent in advance of President Trump’s meeting with Chinese President Xi Jinping on trade matters between the U.S. and China, the members pointed out that Chinese automotive companies have recently accelerated investment in North America and flooded global markets with the long-term goal of dominating market share and controlling automotive manufacturing and supply chains globally. 

Chinese automakers are also heavily subsidized by the Chinese government, creating an unlevel playing field for American automakers, according to their letter.

“We must be clear-eyed about China’s goals in expanding their automotive footprint across the globe. China’s intent is not fair competition, as evident by their actions in other critical sectors,” the members wrote. “They have drastically inflated supply in their domestic auto market through unfair government subsidies and other benefits intended to artificially prop up companies, forcing them to export and expand to foreign markets at below-market prices. 

“China’s goal is not to compete in the U.S. automotive market, but instead to hollow it out and ultimately limit consumer choice to Chinese brands,” they added. “Allowing Chinese automotive and battery companies to manufacture in the U.S. would jeopardize our national security.”

As negotiations with China continue to develop, wrote the members, they urged the administration to reject any attempts by China to establish vehicle and battery manufacturing facilities stateside or in the broader North American market.

Among the lawmakers who joined Rep. Kelly in signing the letter were U.S. Reps. Carol Miller (R-WV), Michael Rulli (R-OH), Troy Balderson (R-OH), Bob Latta (R-OH), John Joyce (R-PA), Brian Fitzpatrick (R-PA), Kat Cammack (R-FL), Ron Estes (R-KS), Andy Barr (R-KY), John Moolenaar (R-MI), Vern Buchanan (R-FL), Ashley Hinson (R-IA), Erin Houchin (R-IN), Buddy Carter (R-GA), Bill Huizenga (R-MI), Darin LaHood (R-IL), Laurel Lee (R-FL), Blake Moore (R-UT), Kevin Hern (R-OK), Pete Stauber (R-MN), Mike Carey (R-OH), and Rudy Yakym (R-IN).

Post navigation

← Previous Article
Next Article →

Source link

FH Capital To Acquire Majority Stake In JinkoSolar’s U.S. Manufacturing Operations

FH Capital announced that it has entered into a definitive agreement to acquire a 75.1% majority stake in Jinko Solar (U.S.) Industries, the U.S. manufacturing subsidiary of JinkoSolar.

Under the agreement, JinkoSolar will retain a 24.9% minority interest in the business. Financial terms of the transaction were not disclosed.

The transaction transfers controlling ownership of JinkoSolar’s U.S.-based 2 gigawatt solar module manufacturing facility along with its growing Battery Energy Storage Systems business.

Following the closing, FH Capital said it plans to invest additional expansion capital to at least double the current solar module manufacturing capacity while also launching domestic BESS manufacturing operations.

According to the companies, the combined platform is intended to address growing U.S. demand for domestically manufactured solar and energy storage products amid evolving clean energy policy initiatives and infrastructure investment trends.

FH Capital is led by Managing Partner Sanjeev Chaurasia, a renewable energy investment banker and investor with more than two decades of industry experience. Chaurasia previously served as Managing Director at Credit Suisse, where he co-founded the firm’s renewable energy practice and led JinkoSolar’s 2010 IPO on the New York Stock Exchange.

JinkoSolar has operated manufacturing operations in the United States for seven years and maintains a global production and sales footprint spanning multiple international markets.

The transaction remains subject to customary closing conditions and regulatory approvals.

Latham & Watkins served as legal counsel to FH Capital. Morgan Stanley Asia acted as financial advisor to JinkoSolar, while Cleary Gottlieb Steen & Hamilton served as legal counsel.

KEY QUOTES:

“The transaction leverages JinkoSolar’s well established seven-year U.S. manufacturing presence, proven technology, and strong relationships with blue-chip U.S. customers, with FH Capital’s capabilities to create and manage a dynamic platform positioned to meet rising demand for domestic solar and storage solutions.”

Sanjeev Chaurasia, Managing Partner, FH Capital

“FH Capital brings deep sector expertise, financing experience, and a deep understanding of the U.S. market.”

“We believe this transaction provides the right ownership, management and strategic direction for this new venture to grow capacity and serve the growing demand for high performance U.S.-sourced renewable energy products.”

Nigel Cockroft, U.S. General Manager, JinkoSolar

Source link

Nvidia CEO says AI partnership with Corning will ‘revitalize American manufacturing’

Nvidia CEO Jensen Huang announced a partnership with Corning aimed at revitalizing American manufacturing by expanding domestic optical connectivity manufacturing. The collaboration will create over 3,000 jobs with new facilities in Texas and North Carolina. Huang emphasized the opportunity to rebuild the technology supply chain in the U.S. amid a significant AI infrastructure buildout, highlighting the increasing demand for skilled workers in various sectors. The partnership focuses on enhancing optical technologies essential for AI data centers, marking a pivotal moment for U.S. manufacturing.

Log in to access the full 0 words article for free

Sign up / Log in

Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.

Source link

US Apparel Manufacturing Fell 17% in 2025

About $300 million in imports to the United States changed country of origin last year—the likely result of volatile tariff policy perpetuated by the Trump administration. Still, even with all the fluctuations in sourcing patterns, U.S. manufacturing output remained essentially flat.

At the same time, manufactured goods imports increased from around $2.85 trillion in 2024 to around $2.98 trillion in 2025—a 4.6 percent jump, according to Kearney’s latest Reshoring Index.

The primary benefactors of that new business were low-cost Asian countries and regions including China, which collectively saw their imports to the U.S. increase by 6 percent. Apparel and accessories imports from the region totaled $88 billion in 2025.

Despite promises that tariffs on these precise trading partners would deter brands from buying and usher in a renaissance for U.S. producers, onshore manufactured goods output (MGO) actually decreased overall by 0.4 percent, or $28 billion. The numbers were even more stark for the apparel sector, which saw MGO fall by 17 percent.

While 75 percent of respondents to the Reshoring Index survey reported pulling sourcing out of China, their business moved regionally to other low-cost Asian countries rather than moving back home. Just 20 percent said they even considered domestic manufacturing.

According to Patrick Van den Bossche, a partner in management consultant Kearney’s Strategic Operations Practice who authored the 2026 Reshoring Index, there are several reasons that apparel imports continue to outpace the growth of domestic production.

“I think there are a couple of things that are different from other industries. First and foremost, I think it’s probably still one of the industries with the lowest [research and development] budgets out there,” he told Sourcing Journal.

When it comes to innovation, like the automation of processes that are currently executed by hand (or by machines directly controlled by hands), “the speed with which I see that happen in other industries is quite a bit higher,” Van den Bossche said. “And that is required to get some of the expensive labor out.”

Then, there’s the fact that “apparel has always been a low margin industry”—a truth as old as time. “You have a whole bunch of elements here, just from a financial perspective, that make it hard for this industry to go through the kind of changes that would need to happen to make it fit for U.S. manufacturing again.”

Offshore sourcing ecosystems for apparel are also deeply embedded after decades of Asia dominance, Kearney’s research surmised. The entrenchment of those supply chains may have been underestimated by proponents of nearshoring and onshoring, while the impacts of higher tariffs may have been overestimated.

Most Asian and Southeast Asian nations were hit with “reciprocal” tariffs that hovered around 20 percent, but the cost pressures were spread throughout the supply chain, with producers bearing some of the burden. As a result, many brands surmised that paying double-digit duties was more cost effective than shifting production to the U.S.

“I think the way it was done created so much turmoil and so much uncertainty that it made it really difficult for company executives to make decisions,” Van den Bossche said of Washington’s tariff strategy, which, throughout 2025, seemed to change weekly.

“Therefore, they went with the least risky one, which is just do more we’ve been doing,” he said. Companies sourcing from Asia remained in Asia, though they did diversify across a number of markets there.

One CEO who responded to the Reshoring Index survey explained, “Our manufacturing teams are ready to run onto the field, we just need the goal posts to stop moving.”

Van den Bossche believes there’s a chance the shifting of goal posts could stop when the U.S. Trade Representative’s Section 301 investigations into forced labor in supply chains and industrial excess capacity wrap up—the administration’s goal being to reconstitute its now-defunct International Emergency Economic Powers Act (IEEPA) duties.

“We have no clue what that will look like until it’s here, but that could create some level of stability where people go, ‘All right, it’s for real now, and these can’t be challenged or hung up in the Supreme Court, so we can believe that this is a new reality and we can plan for that and execute against it,’” he said. “Or it could be done again in the same wild west manner… and we’re back to nothing but a cloud of dust, where nobody sees where they’re going.”

Source link

Lawmakers warn Chinese auto expansion threatens U.S. manufacturing

Republican lawmakers cite economic, supply chain, and cybersecurity concerns ahead of Trump’s Beijing meeting

On the Dash:

• Potential restrictions on Chinese automakers could reshape future EV competition and pricing in the U.S. market
• Ongoing trade tensions may create continued uncertainty around sourcing, tariffs, and inventory planning
• Bipartisan pressure in Washington signals tougher scrutiny of connected vehicle technology and supply chains

Ahead of President Donald Trump’s trip to Beijing next week, dozens of House Republicans are urging the administration to protect the U.S. auto industry from what they describe as unfair Chinese competition and growing national security risks.

In a letter sent to the White House Wednesday, lawmakers warned that allowing Chinese automakers to manufacture or sell vehicles and batteries in the United States could severely damage domestic manufacturing and weaken the country’s economic position.

Sign up for CBT News’ daily newsletter and get the latest industry stories delivered straight to your inbox.

“The automotive industry is a foundational piece of the U.S. economy, contributing upwards of 5% of U.S. GDP and generating millions of manufacturing jobs across the country,” the lawmakers wrote. “The U.S. auto industry is reaching a critical inflection point, as global dynamics and shifts in policy create opportunities for heavily subsidized Chinese automakers to gain momentum using non-market tactics.”

The lawmakers argued that expanded Chinese market access could decimate U.S. manufacturing, erode global market share for U.S. auto companies, and leave consumers and businesses exposed to serious cybersecurity and surveillance threats.

The letter arrives as speculation grows that Chinese auto market access could surface during Trump’s upcoming meeting with Chinese President Xi Jinping in Beijing.

Concern over Chinese automakers has intensified across both parties in Washington. Last week, House Democrats sent a letter to the administration warning that the U.S. must not allow the American auto industry to fall into the hands of a strategic competitor intent on achieving global dominance.

Last month, Sens. Chuck Schumer, Elissa Slotkin and Tammy Baldwin also urged the administration to maintain restrictions on Chinese automakers and connected vehicle technologies.

Slotkin has since joined Republican Sen. Bernie Moreno in sponsoring the Connected Vehicle Security Act, legislation designed to permanently ban Chinese connected vehicle hardware and software from entering the U.S. market under existing Commerce Department rules.

The proposed legislation reflects broader concerns about the growing role of connected vehicle technologies and the potential risks posed by foreign-controlled software, data systems, and supply chains.

Source link

Indian Companies Pledge Record $20.5 Billion Investment in US

3 min readMay 7, 2026 08:40 AM IST

Indian companies have pledged to invest a record $20.5 billion in the United States, which includes $19.1 billion in pharmaceuticals, the US embassy said on Wednesday.

The commitments were made during an investment summit in Maryland, US.

According to the US embassy, the commitments span key sectors including pharmaceuticals, advanced manufacturing, energy infrastructure, and emerging technologies, and are expected to create thousands of jobs in both countries while expanding US production and joint innovation capacity.

The US embassy statement quoted Ambassador Sergio Gor saying, “I am proud to advance our goal to double US-India bilateral trade to $500 billion by 2030. Through fair, balanced, and mutually beneficial trade, we’re attracting world-class investment to the United States and creating shared prosperity for both nations.”

It said that a significant share of the investment is driven by India’s pharmaceutical sector, with more than $19.1 billion in planned investments in US manufacturing, research and development, and new facilities.

In addition, 12 Indian companies announced more than $1.1 billion in new greenfield and expansion projects across multiple states, supporting jobs in manufacturing, technology, and engineering.

Pharmaceuticals & industrial capacity

Indian pharmaceutical companies announced plans to invest more than $19.1 billion in the US, anchored by Sun Pharmaceutical’s planned $11.75 billion acquisition of New Jersey-based Organon & Co. Participating companies include Aurobindo Pharma Ltd, Biocon Group, Cipla Ltd, Dr. Reddy’s Laboratories Ltd, Glenmark Pharmaceuticals Ltd, Granules India Ltd, Jubilant Group, Lupin Ltd, Sun Pharmaceutical Industries Ltd, Piramal Pharma Ltd, and Zydus Lifesciences Ltd, the statement said.

Story continues below this ad

These investments will support manufacturing and network expansions, new greenfield facilities, and increased research and development, helping expand the supply of essential medicines, address drug shortages, and strengthen the resilience of the US healthcare supply chain.

JSW Steel affirmed plans for commissioning $255 million in modernisation projects at its facilities in Ohio and Texas.

Manufacturing

Abhyuday Group (Ahmedabad) will invest over $900 million across five US sites, creating 1,500 American jobs. Jindal Pipe and Jindal Tubular USA (PR Jindal Group) will invest $87 million to expand in Texas and Mississippi, creating 140 jobs. Jivo Wellness (Delhi) will invest $15 million, creating 50 direct jobs and up to 150 indirect jobs.  Polyhose Inc. will invest $2 million in Los Angeles to support the US shipbuilding industry.

Technology, AI, and digital infrastructure

Mumbai-based Sterlite Technologies Ltd will invest $100 million, creating up to 500 jobs and supporting AI and telecom infrastructure.

Techdome Solutions (Indore) will invest $7.5 million, creating 100 jobs.

Story continues below this ad

Kerala’s RoshAi will invest $5 million in Texas, creating 20 jobs. Chennai’s Atri AI will invest $2 million in Menlo Park, California. Kissflow will invest $2 million in Houston. SatoriXR will invest $1.5 million in Michigan, creating 25 jobs.

Energy, research & innovation

MagnoInnovation Lab (Kerala) will invest $2 million to establish US field operations and support energy sector applications. Indian Institute of Technology Madras Global Research Foundation will invest $4.5 million to establish a US research and collaboration hub in California, with plans for an additional East Coast.

Expand

Shubhajit Roy, Diplomatic Editor at The Indian Express, has been a journalist for more than 25 years now. Roy joined The Indian Express in October 2003 and has been reporting on foreign affairs for more than 17 years now. Based in Delhi, he has also led the National government and political bureau at The Indian Express in Delhi — a team of reporters who cover the national government and politics for the newspaper. He has got the Ramnath Goenka Journalism award for Excellence in Journalism ‘2016. He got this award for his coverage of the Holey Bakery attack in Dhaka and its aftermath. He also got the IIMCAA Award for the Journalist of the Year, 2022, (Jury’s special mention) for his coverage of the fall of Kabul in August 2021 — he was one of the few Indian journalists in Kabul and the only mainstream newspaper to have covered the Taliban’s capture of power in mid-August, 2021. … Read More

© The Indian Express Pvt Ltd

Source link

STL invests $100M in US manufacturing capacity

India’s Sterlite Technologies Ltd. (STL) is investing up to $100 million to strengthen its manufacturing capacity in the U.S.

Announced at the SelectUSA Investment Summit, the firm is building out capacity as it bids to strengthen its foothold in connectivity solutions, including terminated optical fiber cables, for AI data centers and telecom customers in the U.S.

STL also claimed the investment is expected to create 400-500 jobs.

“By owning the entire value chain, from glass to data center portfolio, we are excited to enable our customers to build the physical foundation for the AI era”, said Rahul Puri, CEO of STL. “This investment will ensure that the infrastructure required to build a strong AI backbone behind global intelligence is scalable and reliable.”

STL recently launched Neuralis, a suite of connectivity products designed for AI-driven data centers. The platform was framed as a comprehensive connectivity foundation for modern data centers, which are increasingly being built around GPU-intensive architectures and AI training environments. The firm described the offering as a “central nervous system” for these facilities, built to support the higher density and bandwidth requirements tied to AI and hyperscale computing.

The company said Neuralis is designed to respond to changing data traffic patterns in modern data centers, with AI workloads driving a surge in east-west traffic, where data flows between servers internally. Neuralis is engineered to support this shift through higher-density, high-speed connectivity.

STL also highlighted its vertically integrated manufacturing model with the release, touting that it manages the entire production lifecycle spanning across glass preform fabrication and fiber drawing, to cabling and final connector assembly.

Source link